Adam D. Griesemer, MD

Expertise in: 
Transplant Surgery, Liver & Abdominal Transplant Surgery
Board Certifications: 
Surgery
Accepting New Patients
Treats Children
Virtual Visits/Telehealth
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

  • Abdominal Organ Transplant, Pediatric
  • Abdominal Organ Transplantation
  • Hepatobiliary Surgery
  • Liver Transplant
  • Liver Transplant, Pediatric
  • Living Donor Liver Surgery
  • Living Donor Transplantation
  • Minimally Invasive Liver Surgery
  • Organ Transplant, Pediatric
  • Pediatric Transplant Surgery
  • Portal Hypertension
  • Shunts
  • Transplantation Surgery

Academic Appointments

  • Assistant Professor of Surgery at CUMC

Administrative Titles

  • Surgical Director, Pediatric Liver Transplantation
  • Surgical Director, Living Donor Liver Transplantation-Columbia Campus
  • Director, Large Animal Xenotransplantation Laboratory, Columbia Center for Translational Immunology

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian Morgan Stanley Children's Hospital
  • NewYork-Presbyterian / Weill Cornell Medical Center
  • NewYork-Presbyterian Lawrence Hospital
  • NewYork-Presbyterian Allen Hospital

Gender

  • Male

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

622 West 168th Street
PH, Floor 14
New York, NY 10032
Primary
Phone:

Insurance Accepted

Aetna

  • Aetna Signature Administrators
  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Student Health

Affinity Health Plan

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs

Amida Care

  • Special Needs

Cigna

  • EPO
  • Great West (National)
  • HMO
  • POS
  • PPO

Elderplan

  • Medicare Managed Care

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross/Blue Shield

  • EPO
  • HMO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare

Medicare

  • Railroad
  • Traditional Medicare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

Quality Health Management

  • Quality Health Management

RiverSpring

  • Special Needs

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • Empire Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • University of Missouri Columbia School of Medicine
  • BA, Harvard University
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: 2013 Department of Surgery, Columbia University, Abdominal Organ Transplant Fellow

Board Certifications

  • Surgery

Honors & Awards

  • 2020 New York Super Doctors
  • 2020 Rising Star in Transplant Surgery, American Society of Transplant Surgery 2020
  • 2019 Co-Chair, Surgical Committee of The Starzl Network for Excellence in Pediatric Transplantation
  • 2018 Faculty Development Grant, American Society of Transplant Surgeons
  • 2017 Nominated for Physician of the Year by Surgical Intensive Care Unit
  • 2015 AASLD Career Development Award in Liver Transplantation
  • 2013 Forde Award for Research, Columbia University
  • 2013 Department of Surgery's Chairman's Research Award, Columbia University College of Physicians and Surgeons
  • 2013 Louis V. Gerstner, Jr. Scholar – Research Award, Columbia University College of Physicians and Surgeons
  • 2011 Blakemore Prize - Best Resident Research Award, Columbia University College of Physicians and Surgeons
  • 2010 Administrative Chief Resident in General Surgery, Columbia University
  • 2009 Blakemore Award - Best Resident Research Award, Columbia University College of Physicians and Surgeons
  • 2008 American Society of Transplantation Young Investigator Award, Transplantation Biology Research Center, Harvard Medical School
  • 2007 International Xenotransplantation Travel Grant, Transplantation Biology Research Center, Harvard Medical School
  • 2005 American Society of Transplantation/JDRF Research Fellowship Award, Transplantation Biology Research Center, Harvard Medical School
  • 2003 Alpha Omega Alpha, University of Missouri-Columbia School of Medicine

Research

Allogeneic Studies

My laboratory is investigating the ability of ex-vivo expanded Tregs to enhance bone marrow engraftment and extend the duration of mixed chimerism. The induction of durable mixed chimerism without graft-versus-host disease should in turn lead to life-long donor-specific tolerance to any co-transplanted cells (islets) or solid organs (heart, liver, lung) from the donor. We are also collaborating with other investigators at the CCTI to study the ability of amnion-derived multipotent progenitor cells to enhance bone marrow engraftment in translational models as an alternate, and potentially synergistic, strategy to induce durable mixed chimerism.

We are also investigating the ability to translate the induction protocol that induces tolerance to simultaneously co-transplanted bone marrow and kidney grafts (despite only transient mixed chimerism developing) to combined bone marrow and liver grafts. In particular, we are investigating 1) the role of donor and recipient memory cells in mediating host-versus-graft and graft-versus-host responses; and 2) the role that inflammatory cytokines, particularly in the portal system, play in priming inflammatory and tolerogenic cellular responses.

The future goals of the laboratory include collaborating with the Chen lab in testing the ability of durable mixed chimerism to induce tolerance to organs that do not facilitate tolerance with the transient mixed chimerism approach, such as islets. We also plan to test the ability of modulating the T cell memory responses and the inflammatory environment induced after liver transplant to reliably induce rapid tolerance after liver transplants.

Xenogeneic Studies

The development of Gal-knockout swine removed the most significant target of natural antibodies from the surface of pig cells. However, low levels of non-Gal antibodies represent a barrier to long-term solid organ xenograft survival and xenogeneic bone marrow engraftment. Since pharmacological interventions have been unsuccessful in decreasing natural antibody levels, my lab is investigating the efficacy of Treg therapy in reducing anti-swine antibodies and facilitating tolerance induction to xenotransplants.

Current investigations include:

1. Studies on the optimal method of stimulating Tregs during expansion to generate donor-specific Tregs

2. Suppression of xenogeneic natural antibodies by donor-specific Tregs in preclinical models

3. Augmentation of xenogeneic chimerism using donor-specific Tregs

The future goals of the laboratory are to utilize donor-specific Tregs to control the natural anti-swine antibody response in translational swine-to-humanized mice and swine-to-nonhuman primate models. This in turn will facilitate the induction of xenogeneic chimerism that is expected to result in robust tolerance to donor solid organ transplants.

Research Interests

  • Allogeneic tolerance induction
  • Control of humoral rejection
  • Small for Size Syndrome after Living Donor Liver Transplantation
  • Use of Tregs to control natural antibody responses and facilitate xenogeneic bone marrow engraftment
  • Xenogeneic tolerance induction via mixed chimerism and thymus transplant

Selected Publications

  1. Sakai H, Duggan E, Griesemer A. Size isn’t everything: “Small” LDLT grafts can have good outcomes. Transplantation 2020. Invited Commentary, In Press.
  2. Bruestle K, Griesemer A. Pediatric Liver Transplantation in a Center That is Neither East Nor West. Annals of Surgery 2020. In Press.
  3. Alonso-Gullart P, Llore N, Lopes E, Kofman S, Ho S, Stern J, Pierre G, Bruestle K, Tang, Q, Sykes M, Griesemer A. CD40L-stimulated B cells for ex vivo expansion of polyspecific nonhuman primate regulatory T cells for translational studies. Clinical and Experimental Immunology. 2020 In Revision.
  4. Duggan EM, Griesemer A. Progress towards xenogeneic tolerance. Current Opinion in Organ Transplantation 2020. PMID: 32796179
  5. Hozain AE, O’Neill JD, Pinezich MR, Tipograf U, Donocoff R, Cunningham KM, Tumen A, Fung K, Ukita R, Simpson M, Reimer JA, Ruiz EC, Queen D, Stokes JW, Cardwell NK, Talackine J, Snoeck H, Chen Y, Romanov, A, Marboe CC, Griesemer AD, Guenthart BA, Bacchetta M, Vunjak-Novakovic G. Xenogeneic cross-circulation for extracorporeal recovery of injured human lungs. Nature Medicine. 2020 Jul;26(7):1102-1113. PMID: 32661401
  6. Kato T, Hwang R, Liou P, Weiner J, Griesemer A, Samstein B, Halazun K, Mathur A, Schwartz G, Cherqui D, Emond J. Ex vivo resection and autotransplantation for conventionally unresectable tumors – an 11-year single center experience. Annals of Surgery. 2020. PMID: 32833756
  7. Heinz N, Griesemer A, Kinney J, Vittorio J, Lagana S, Golder D, Velasco M, Kato T, Lobritto S, Martinez M. A case of infant with SARS-CoV-2 hepatitis early after liver transplantation. Pediatric Transplantation. 2020. PMID: 32559354, PMCID: PMC7323125
  8. Lagana SM, De Michele S, Lee MJ, Emond JC, Griesemer AD, Tulin-Silver SA, Verna EC, Martinez M, Lefkowitch JH. COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation. Archives of Pathology and Laboratory Medicine. 2020 Apr 17. PMID: 32302212
  9. Chaudhry S, Kato Y, Weiner J, Alonso-Guallart P, Baker S, Woodland DC, Lefkowitch JH, Duran-Struuck R, Sondermeijer HP, Zitsman J, Sears ML, Wu A, Karolewski B, Houck PJ, Martinez M, Kato T, Sykes M, Griesemer AD. In contrast to kidney, liver allograft tolerance is not achieved with a transient mixed chimerism regimen in nonhuman primates. Transplantation. 2020 Apr 6. Epub ahead of print. PMID: 32265416
  10. Winer L, Vivero M, Scully B, Cortez A, Kassam A, Nowygrod R, Griesemer A, Emond JE, Quill-in R. Exploring medical students' perceptions of organ procurement: Need for a formalized medical student curriculum. Journal of Surgical Education. J Surg Educ. 2019 Nov 18. PMID: 31753606
  11. Sell-berg F, Berglund D, Binder C, Hope J, Fontenot J, Griesemer A, Sykes M, Sachs DH, Berglund E. Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody. Scand J Immunol. 2019 Oct 20:e12839. PMID: 31630416
  12. Berglund E, Alonso-Guallart P, Danton M, Sellberg F, Binder C, Fröbom R, Berglund D, Llore N, Sakai H, Iuga A, Ekanayake-Alper D, Reimann KA, Sachs DH, Sykes M, Griesemer A. Safety and pharmacodynamics of anti-CD2 monoclonal antibody treatment in cynomolgus macaques. Transpl Int. 2019 Sep 15. PMID: 31523849